A series of severe necrotising soft-tissue infections in a regional centre in Sweden

2014 ◽  
Vol 58 (7) ◽  
pp. 882-890 ◽  
Author(s):  
M. BRINK ◽  
P. ARNELL ◽  
H. LYCKE ◽  
A. ROSEMAR ◽  
L. HAGBERG
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Infections ◽  
Regional Centre ◽  
Necrotising Soft Tissue Infections

scholarly journals Incidence, comorbidity and mortality in patients with necrotising soft-tissue infections, 2005–2018: a Danish nationwide register-based cohort study

BMJ Open ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. e041302
Author(s):  
Morten Hedetoft ◽  
Martin Bruun Madsen ◽  
Lærke Bruun Madsen ◽  
Ole Hyldegaard
Keyword(s):  
Soft Tissue ◽  
High Volume ◽  
Population Based ◽  
Treatment Modalities ◽  
Soft Tissue Infections ◽  
Registration System ◽  
Female Sex ◽  
High Volume Hospital ◽  
Comorbidity Index ◽  
Necrotising Soft Tissue Infections

ObjectiveTo assess the incidence, comorbidities, treatment modalities and mortality in patients with necrotising soft-tissue infections (NSTIs) in Denmark.DesignNationwide population-based registry study.SettingDenmark.ParticipantsDanish residents with NSTI between 1 January 2005 and 31 August 2018.Main outcome measureIncidence of disease per 100 000 person/year and all-cause mortality at day 90 obtained from Danish National Patient Registry and the Danish Civil Registration System.Results1527 patients with NSTI were identified, yielding an incidence of 1.99 per 100 000 person/year. All-cause 30-day, 90-day and 1-year mortality were 19.4% (95% CI 17.4% to 21.5%), 25.2% (95% CI 23.1% to 27.5%) and 30.4% (95% CI 28.0% to 32.8%), respectively. Amputation occurred in 7% of the individuals. Diabetes was the most predominant comorbidity affecting 43% of the cohort, while 26% had no comorbidities. Higher age, female sex and increasing comorbidity index were found to be independent risk factors of mortality. Admission to high-volume hospitals was associated with improved survival (OR 0.59, 95% CI 0.45 to 0.77). Thirty-six per cent received hyperbaric oxygen therapy (HBOT) as an adjunctive therapy. No change in overall mortality was found over the studied time period.ConclusionThe present study found that in Denmark, the incidence of NSTI increased; mortality rates remained high and largely unaltered. Diabetes was the most common comorbidity, while higher age, female sex and increasing comorbidity index were associated to increased mortality. Survival was improved in those admitted to hospitals with more expertise in treating NSTI. In high-volume hospital, HBOT was associated with decreased odds for mortality.

scholarly journals Necrotising Soft Tissue Infections: The Effect of Hyperbaric Oxygen on Mortality

2015 ◽  
Vol 43 (6) ◽  
pp. 685-692 ◽  
Author(s):  
B. Devaney ◽  
G. Frawley ◽  
L. Frawley ◽  
D. V. Pilcher
Keyword(s):  
Soft Tissue ◽  
Hyperbaric Oxygen ◽  
Soft Tissue Infections ◽  
Necrotising Soft Tissue Infections

Diagnostic Confusion in Periorbital Necrotising Soft Tissue Infections

Orbit ◽  
2014 ◽  
Vol 33 (3) ◽  
pp. 236-236
Author(s):  
Jonathan Pollock ◽  
Abdul Rahman Hassan ◽  
Matt Smith
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Infections ◽  
Diagnostic Confusion ◽  
Necrotising Soft Tissue Infections

scholarly journals Biodegradable temporising matrix for necrotising soft tissue infections: a case report

2019 ◽  
Vol 2 (1) ◽  
pp. 106-109 ◽  
Author(s):  
Sadhishaan Sreedharan ◽  
Edwin Morrison ◽  
Heather Cleland ◽  
Sophie Ricketts ◽  
Frank Bruscino-Raiola
Keyword(s):  
Soft Tissue ◽  
Oxygen Therapy ◽  
Reconstruction Technique ◽  
Soft Tissue Infections ◽  
Split Skin Graft ◽  
Dermal Matrix ◽  
Radical Debridement ◽  
Split Skin ◽  
Complex Wounds ◽  
Necrotising Soft Tissue Infections

Necrotising soft tissue infection (NSTI) is a rapidly progressing disease that presents a surgical emergency. Timely antibiotics, radical debridement of infected tissues and adjuvant hyperbaric oxygen therapy are the foundations of its treatment. Split-skin graft (SSG) is the main reconstruction technique due to its simplicity and dependability. Dermal substitutes, as well as creating a suitable wound bed for grafting, aim to recreate the inherent thickness and pliability of skin. One innovation, Novosorb™ (produced by PolyNovo Ltd, Port Melbourne, Australia), is a biodegradable temporising matrix (BTM) that is an entirely synthetic implantable dermal matrix that creates a neo-dermis in complex wounds. 

Sign in / Sign up

Export Citation Format

Share Document